Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM)

• Status: Completed
• Trial end date: 2009-07-01

Summary

The primary objective of this trial is to show that PTH(1-84) is superior to strontium ranelate in bone formation measured as changes in bone formation markers over a treatment period of 24 weeks in postmenopausal women with primary osteoporosis.

• Phase: Phase 4

Details

• Lead Sponsor: Nycomed
• Treatments: Hormones; Parathyroid Hormone; Strontium ranelate